Stay updated on MK-3475 Maintenance in Extensive SCLC Clinical Trial

Sign up to get notified when there's something new on the MK-3475 Maintenance in Extensive SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MK-3475 Maintenance in Extensive SCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:50:14.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record of a phase II trial evaluating the effectiveness of pembrolizumab in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:51:38.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, the inclusion criteria now specify that patients must have completed at least 4 cycles of platinum and etoposide chemotherapy as their first line therapy.
    Difference
    47%
    Check dated 2024-05-22T21:37:16.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:34:49.000Z thumbnail image

Stay in the know with updates to MK-3475 Maintenance in Extensive SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MK-3475 Maintenance in Extensive SCLC Clinical Trial page.